Pharmos&#39; Disappointing Brain-Injury Treatment
494911
NEW YORK - Hopes for an experimental treatment that had the potential to help the 85,000 Americans who suffer long-term disability each year due to traumatic brain injury were dashed this morning when Pharmos said that its drug, dexanabinol, failed to
84689
The drugs most widely used to manage aggressive outbursts in intellectually disabled people are no more effective than placebos for most patients and may be less so.
688076
Because of PfizerÂs failed trial, drugs similar to torcetrapib from other companies could face greater scrutiny Â and delays Â in getting to market.
239946
The spate of bad news about painkillers has dealt a major setback to what had been a highly promising effort to use the drugs to prevent a host of leading killers, including many types of cancer, Alzheimer&#39;s and other forms of dementia.
457847
WASHINGTON - The spate of bad news about painkillers has dealt a major setback to what had been a highly promising effort to use the drugs to prevent a host of leading killers, including many types of cancer, Alzheimer&#39;s and other forms of dementia.
670072
A drug called t-PA can dissolve a brain-damaging blood clot, but only if itÂs used in time.
575599
Patients losing their sight say they are being denied access to a drug which could stop them from going blind.
112421
The medical profession has a costly, little-known secret: Many treatments don&#39;t work all that well for many -- even most -- people.
12314
Its Alzheimer's treatment flops in testing, on the heels of FDA disapproval of another Neurochem drug.
82904
SHANGHAI -- Looking at the facts, the past year seems to have been disastrous for Worldbest Pharmaceutical.  First, there were reports of accounting irregularities and exaggerated profit. Half the managers were fired. Then, in the summer, six people died and at least 80 fell ill after receiving an antibiotic injection manufactured by a subsidiary. Most recently, the company warned investors that it was likely to report its third consecutive year of losses....
646800
Gaithersburg-based GenVec has run into a problem with its top drug candidate, and investors have had an adverse reaction. GenVec says the US Food and Drug Administration has requested that clinical trials
251130
Neurologists urge caution upon reports of a successful therapy.
426952
Dopamine is the mainstay of treatment for people with Parkinson&#39;s disease, but it comes with a down side. Dopamine-based therapy impairs the brain&#39;s ability to respond
80657
Anti-inflammatory drugs routinely given to patients with serious head injuries may have killed 10,000 people over the past few decades, according to research.
468846
A few years ago, drug giant Bristol-Myers Squibb Co. announced it was retooling its strategy, meaning a drug it was developing for insomnia was probably headed for the sidelines. Vanda Pharmaceuticals Inc. pounced.
122895
Drug stocks across the board fell amid renewed safety concerns over a class of blockbuster drugs used to treat arthritis. Preprint articles published on the New England Journal of Medicine&#39;s Web site Wednesday
79583
Bristol-Myers Squibb Co. said an experimental treatment it is developing with Corgentech Inc. to treat vein grafts proved no better than a placebo in a late-stage clinical trial.